As adversaries weaponize AI against the systems organizations depend on, IBM is putting cutting-edge defenses in the hands of clients…
100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET |…
ATLANTA, May 04, 2026 (GLOBE NEWSWIRE) -- ApolloMD has helped eliminate more than $1.5 billion in patient medical debt since…
April 26, 2026 12:00 ET | Source: Oruka Therapeutics, Inc. MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka…
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…
San Francisco, CA, Dec. 23, 2025 (GLOBE NEWSWIRE) -- PULSESUN Trading Center has completed a series of infrastructure and system-level…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
October 24, 2025 11:39 ET | Source: PMV Pharmaceuticals, Inc. Data presented today as an oral presentation at 2025 AACR-NCI-EORTC…
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable…